Buprenorphine for human immunodeficiency virus/Hepatitis C virus-coinfected patients: Does it serve as a bridge to hepatitis C virus therapy?

Journal of Addiction Medicine

Volumn 6, Issue 3, 2012, Pages 179-185

  Taylor, Lynn E ^a   Maynard, Michaela A ^b   Friedmann, Peter D ^c   MacLeod, Cynthia J ^b   Rich, Josiah D ^a   Flanigan, Timothy P ^a   Sylvestre, Diana L ^d  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; HCV treatment; Hepatitis C virus (HCV); HIV HCV coinfection; Opioid replacement therapy

Indexed keywords

ALPRAZOLAM; ANTIRETROVIRUS AGENT; BUPRENORPHINE; EMTRICITABINE PLUS LOPINAVIR PLUS RITONAVIR PLUS TENOFOVIR; FLUOXETINE; HEPATITIS C ANTIBODY; LITHIUM CARBONATE; METHADONE; PEGINTERFERON; PEGYLATED INTERFERON PLUS RIBAVIRIN; QUETIAPINE; SULFAMETHOXAZOLE; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS RNA;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CD4 LYMPHOCYTE COUNT; COCAINE DEPENDENCE; CONTROLLED STUDY; DEPRESSION; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEROIN DEPENDENCE; HIATUS HERNIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; JAUNDICE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MENTAL HEALTH; MIXED INFECTION; OPIATE ADDICTION; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS NEUTRALIZATION; WELLBEING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; BUPRENORPHINE; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84871313381     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e318257377f     Document Type: Article

References (44)

1. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003;138:187-190.
2. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIVinfected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011;56(suppl 1):S22-S32.
3. Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS 2005;19(suppl 3):S13-S19.
4. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-516.e501.
5. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50:407-413.
6. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988;43:72-78.
7. Bonkovsky H, Tice A, Yapp R, et al. Efficacy and safety of peginterferon alfa- 2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 2008;103:2757-2765.
8. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-587.
9. Cheever LW, Kresina TF, Cajina A, Lubran R. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr 2011;56(suppl 1):S3-S6.
10. Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol 2009;43:686-691.
11. Chossegros P, Melin P, Hezode C, et al. A French prospective observational study of the treatment of chronic hepatitis C in drug abusers. Gastroenterol Clin Biol 2008;32:850-857.
12. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 2004;38(suppl 5):S402-S408.
13. de Ledinghen V, Barreiro P, Foucher J, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIVnegative patients despite antiretroviral therapy. J Viral Hepat 2008;15: 427-433.
14. Edlin B, Kresina T, Raymond D, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005;40(suppl 5):S276-S285.
15. Falck-Ytter Y, Kale H, Mullen K, Sarbah S, Sorescu L, McCullough A. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-292.
16. Friedmann PD, Lemon SC, Stein MD,D'Aunno TA.Accessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizations. Health Serv Res 2003;38:887-903.
17. Ghany M, Strader D, Thomas D, Seeff L. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
18. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS 2005;19(suppl 3):S99-S105.
19. Grebely J, Raffa J, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007;22:1519-1525.
20. GruberVA, Rainey PM,Moody DE, et al. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clin Infect Dis 2012;54(3):414-423.
21. Gryczynski J, Schwartz R, O'Grady K, Jaffe J. Treatment entry among individuals on a waiting list for methadone maintenance. Am J Drug Alcohol Abuse 2009;35:290-294.
22. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35:501-516.
23. Litwin A, Harris KJ, Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009;37: 32-40.
24. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-224.
25. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120-124.
26. McCance-Katz EF, Mandell TW. Drug interactions of clinical importance with methadone and buprenorphine. Am J Addict 2010;19:2-3.
27. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reversetranscriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 2006a;43(suppl 4):S224-S234.
28. McCance-Katz EF, Moody DE, Smith PF, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 2006b;43(suppl 4):S235-S246.
29. Moatti JP, CarrieriMP, Spire B, Gastaut JA, Cassuto JP,Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. TheManif 2000 Study Group. AIDS 2000;14:151-155.
30. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007;46:622-630.
31. Rosenberg SD, Drake RE, Brunette MF, Wolford GL, Marsh BJ. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS 2005;19(suppl 3):S26-S33.
32. Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 2011;106:977-984.
33. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-288, 288.e1.
34. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002;16:813-828.
35. Sulkowski MS, Cheever LW, Spach DH. A Guide for Evaluation and Treatment of Hepatitis C in Adults Coinfected With HIV. Washington, DC, US Department of Health and Human Services 2011; Health Resources and Services Administration.
36. Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis 2005;41:891-896.
37. Sylvestre D, Clements B. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007;19:741-747.
38. Sylvestre DL, Barrett L, Asher A, Hartfield L, Klem B, Cohen JB. Bridging high-risk heroin users to hepatitis C treatment using buprenorphine. Posterpresentation at: 55th Annual Meeting of the American Association for the Study of Liver Disease; October 30, 2004, Boston, MA. Poster 391.
39. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007;18:406-410.
40. Taylor LE, Bowman SE, Chapman S, et al. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug Alcohol Depend 2011;116(1-3):233-237.
41. Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr 2011;56(suppl 1):S62-S67.
42. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010;38:338-345.
43. Weber R, Sabin CA, Früs-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-1641.
44. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35:253-259.